Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2026-01-23 @ 11:07 AM
Study NCT ID:
NCT03769467
Status:
TERMINATED
Last Update Posted:
2024-11-14
First Post:
2018-11-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Sponsor:
Atara Biotherapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-19
Start Date Type:
ACTUAL
Primary Completion Date:
2021-08-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-08-19
Completion Date Type:
ACTUAL
First Submit Date:
2018-11-29
First Submit QC Date:
None
Study First Post Date:
2018-12-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-06-04
Results First Submit QC Date:
None
Results First Post Date:
2024-11-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-11-14
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-11-08
Last Update Post Date:
2024-11-14
Last Update Post Date Type:
ACTUAL